Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Phase 1 Terminated 13 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Io Therapeutics · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the use of IRX5183 in 1) patients with relapsed and/or refractory AML and 2) patients with high-risk MDS or chronic myelomonocytic leukemia (CMML).

Timeline

Start: 2017-01-30
Primary completion: 2018-08-14
Completion: 2018-08-14

Outcome

Outcome not reported

Stopped: “Study drug supply expired and could not be renewed.”

Publications

Ambinder AJ, Norsworthy K, Hernandez D, Palau L, Paun B, Duffield A, Chandraratna R, Sanders M, Varadhan R, Jones RJ, Douglas Smith B, Ghiaur G. A Phase 1 Study of IRX195183, a RARalpha-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. Front Oncol. 2020 Oct 23;10:587062. doi: 10.3389/fonc.2020.587062. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NRX 195183	Small molecule	50 mg	Oral
Subject	NRX 195183	Small molecule	75 mg	Oral
Subject	NRX 195183	Small molecule	100 mg	Oral